Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Randomised, double-blind, placebo-controlled, parallel group, multicentre study of oral doses
of V3381, titrated to effect. A 2-week single-blind run-in period will be followed by a 13
week double-blind titration and maintenance phase. Doses will be titrated up in 100 mg bid
increments every one or two weeks, starting from 100 mg bid. A 2 week follow-up period will
conclude patient participation in the study.